Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
U.S. FDA has granted Orphan Drug Designation for Cellusion CLS001, a therapeutic regenerative medicine product. It is currently undergoing IND Enabling studies for the treatment of bullous keratopathy.
Lead Product(s): CLS001
Therapeutic Area: Ophthalmology Product Name: CLS001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2023
Details:
Under the Agreement, Celregen will have the exclusive right to develop, manufacture and commercialize CLS001 for bullous keratopathy in the Greater China region, including Mainland China, Hong Kong, Macau and Taiwan.
Lead Product(s): CLS001
Therapeutic Area: Ophthalmology Product Name: CLS001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Hangzhou Celregen Therapeutics
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 12, 2022